BRPI0606395A2 - conjugados para ambas imagem e radioquimioterapia: composição, fabricação e aplicações - Google Patents

conjugados para ambas imagem e radioquimioterapia: composição, fabricação e aplicações

Info

Publication number
BRPI0606395A2
BRPI0606395A2 BRPI0606395-0A BRPI0606395A BRPI0606395A2 BR PI0606395 A2 BRPI0606395 A2 BR PI0606395A2 BR PI0606395 A BRPI0606395 A BR PI0606395A BR PI0606395 A2 BRPI0606395 A2 BR PI0606395A2
Authority
BR
Brazil
Prior art keywords
imaging
radiotherapy
manufacture
applications
compounds
Prior art date
Application number
BRPI0606395-0A
Other languages
English (en)
Inventor
Dongfang Yu
Mithu Chanda
Ali Azhdarinia
Changsok Oh
David J Yang
E Edmund Kim
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of BRPI0606395A2 publication Critical patent/BRPI0606395A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicinal Preparation (AREA)

Abstract

CONJUGADOS PARA AMBAS IMAGEM E RADIOQUIMIOTERAPIA: COMPOSIçãO, FABRICAçãO E APLICAçõES. Composições e métodos para a dupla imagem e tanto para quimioterapia como para radioterapia são descritas. Mais particularmente, a presente invenção se refere a compostos que compreendem uma estrutura X~ 1~-Y-X~ 2~, onde Y compreende dois ou mais resíduos de carboidrato covalentemente ligados um ao outro, X~ 1~ e X~ 2~ são frações diagnosticas ou terapêuticas covalentemente ligadas a Y, desde que quando Y não compreende um resíduo de glicosamina, X~ 1~ e X~ 2~ são frações diagnósticas. A presente invenção se refere também a métodos de síntese dos referidos compostos, aplicação dos referidos compostos tanto para a imagem como para o tratamento de doenças hiper-prolíferativas, e kits para a preparação de um composto terapêutico ou diagnostico radiomarcado.
BRPI0606395-0A 2005-01-05 2006-01-05 conjugados para ambas imagem e radioquimioterapia: composição, fabricação e aplicações BRPI0606395A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64155905P 2005-01-05 2005-01-05
PCT/US2006/000269 WO2006074272A2 (en) 2005-01-05 2006-01-05 Conjugates for dual imaging and radiochemotherapy: composition, manufacturing, and applications

Publications (1)

Publication Number Publication Date
BRPI0606395A2 true BRPI0606395A2 (pt) 2009-06-23

Family

ID=36648161

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606395-0A BRPI0606395A2 (pt) 2005-01-05 2006-01-05 conjugados para ambas imagem e radioquimioterapia: composição, fabricação e aplicações

Country Status (11)

Country Link
US (2) US8147805B2 (pt)
EP (1) EP1846042A2 (pt)
JP (1) JP2008531755A (pt)
KR (1) KR101313712B1 (pt)
CN (1) CN101137398B (pt)
AU (2) AU2006204045B2 (pt)
BR (1) BRPI0606395A2 (pt)
CA (1) CA2593256A1 (pt)
IL (1) IL184415A0 (pt)
NO (1) NO20074025L (pt)
WO (1) WO2006074272A2 (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067111B1 (en) * 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
RU2316349C2 (ru) 2001-05-02 2008-02-10 Пердью Рисерч Фаундейшн Лечение и диагностика заболеваний, опосредованных макрофагами
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
JP4680185B2 (ja) 2003-05-30 2011-05-11 パーデュー・リサーチ・ファウンデーション アテローム性動脈硬化症の診断法
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
ITMI20040928A1 (it) 2004-05-07 2004-08-07 Uni Di Bologna Dipartiment O D Procedura per la preparazione di coniugati della doxorubicina con l'albumina umana lattosaminata
WO2006071754A2 (en) * 2004-12-23 2006-07-06 Purdue Research Foundation Positron emission tomography imaging method
US8703097B2 (en) * 2005-02-11 2014-04-22 University Health Network Compositions and method for multimodal imaging
US9820986B2 (en) * 2005-03-04 2017-11-21 Taiwan Hopaz Chems, Mfg. Co., Ltd. Glycopeptide compositions
US20070009434A1 (en) 2005-07-05 2007-01-11 Low Philip S Imaging and therapeutic method using monocytes
ITMI20051743A1 (it) * 2005-09-20 2007-03-21 Uni Di Bologna Dipartimento Di Patologia Spa Uso di coniugati della doxorubicina con albumina lattosaminata
US8795633B2 (en) * 2005-09-23 2014-08-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
WO2007126730A1 (en) * 2006-03-29 2007-11-08 Isotherapeautics Group Llc Radionuclide therapy for urinary bladder cancer
BRPI0621580B8 (pt) * 2006-04-19 2021-05-25 Univ Texas composto derivado de n4 e kit compreendendo o referido composto e um agente redutor
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
CA2668197A1 (en) 2006-11-03 2008-05-15 Philip S. Low Ex vivo flow cytometry method and device
WO2008064040A2 (en) * 2006-11-22 2008-05-29 The Board Of Regents Of The University Of Texas System Methods and compositions using chelator-antibody conjugates
EP2567711A3 (en) 2007-02-07 2013-05-01 Purdue Research Foundation Positron emission tomography imaging method
AU2008230771B2 (en) * 2007-03-27 2014-05-08 Radiomedix Inc. Compositions for targeted imaging and therapy
WO2008148001A2 (en) * 2007-05-25 2008-12-04 Purdue Research Foundation Method of imaging localized infections
US20120277409A1 (en) * 2007-06-04 2012-11-01 Board Of Regents, The University Of Texas System Metal-polysaccharide conjugates: compositions, synthesis and methods for cancer therapy
GB0725070D0 (en) * 2007-12-21 2008-01-30 Iopharma Technologies Ab Product
DE102008045937B4 (de) * 2008-04-11 2017-01-26 Johannes-Gutenberg-Universität Mainz Radiopharmakon aus einem Metallion und einem Markierungsvorläufer und Verwendung des Radiopharmakons
US20090264753A1 (en) * 2008-04-22 2009-10-22 General Electric Company Method & system for multi-modality imaging of sequentially obtained pseudo-steady state data
US9061077B2 (en) * 2008-05-05 2015-06-23 Emory University Methods of determining renal function using technetium-99m tricarbonyl-nitrilotriacetic acid
RU2498278C2 (ru) * 2008-07-09 2013-11-10 Конинклейке Филипс Электроникс Н.В. Физиологический фармакокинетический анализ для комбинированной молекулярной магнитно-резонансной томографии и динамической позитронно-эмиссионной томографии
US20120076728A1 (en) * 2009-04-08 2012-03-29 The Regents Of The University Of California Human protein scaffold with controlled serum pharmacokinetics
JP2011063572A (ja) * 2009-09-18 2011-03-31 Kyushu Univ 診断用造影剤
KR100991716B1 (ko) * 2009-10-22 2010-11-04 경북대학교 산학협력단 광학영상 조영제, 그 용도 및 장치
WO2011090710A2 (en) 2009-12-28 2011-07-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Composite probes and use thereof in super resolution methods
WO2011155805A2 (ko) * 2010-06-11 2011-12-15 국립암센터 종양 및 감시림프절에 특이적인 방사성동위원소 표지된 엽산 결합 인혈청 알부민
CN102218150B (zh) * 2010-08-17 2013-01-30 扬州大学 肝靶向纳米Fe3O4MRI造影剂及制备方法
CN102398026B (zh) * 2010-09-10 2013-10-23 聚和国际股份有限公司 甲壳素修饰的纳米金粒子及其制造方法
CN102558291B (zh) * 2010-12-17 2014-03-12 北京大学人民医院 一种双模分子影像探针
JP2014522808A (ja) * 2011-06-17 2014-09-08 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク 二官能性ホスホネートキレート剤
WO2012177701A2 (en) 2011-06-20 2012-12-27 Radiomedix Inc. Compositions, methods of synthesis and use of carbohydrate targeted agents
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US9725716B2 (en) * 2011-12-06 2017-08-08 Ohio State Innovation Foundation and Research Institute at Nationwide Children's Hospital Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease
RU2674673C2 (ru) * 2012-03-26 2018-12-12 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Эффективный синтез конъюгатов этилендицистеина-сахара для визуализации и терапии
WO2014013729A1 (en) * 2012-07-20 2014-01-23 Canon Kabushiki Kaisha Contrast agent for photoacoustic imaging
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
CN104854134B (zh) * 2012-12-12 2018-01-02 索尔维特殊聚合物意大利有限公司 氟化壳聚糖衍生物
US10035009B2 (en) 2013-04-15 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treating pancreatic cancer
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
US9850183B2 (en) 2014-06-27 2017-12-26 Reiley Pharmaceuticals, Inc. Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging
BE1021191B1 (fr) * 2014-08-29 2015-10-27 Anmi S.A. Kit pour radiomarquage.
US11027030B2 (en) 2014-08-29 2021-06-08 Anmi S.A. Kit for radiolabelling
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
US10053478B2 (en) 2015-01-09 2018-08-21 Reiley Pharmaceuticals, Inc. COX-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
US10905783B2 (en) 2015-11-27 2021-02-02 Michal RIVLIN Glucosamine and derivatives thereof in imaging
CN108761078A (zh) * 2018-05-19 2018-11-06 复旦大学 胰腺癌基底微绒毛的检测方法和应用
IL271681A (en) 2018-07-18 2020-01-30 Vyripharm Entpr Llc Systems and methods for integrated and comprehensive management of cannabis products
KR20200047321A (ko) 2018-10-26 2020-05-07 전남대학교병원 체내위치확인을 위한 풍선확장조성물 및 시스템
CN110563859B (zh) * 2019-09-19 2021-07-23 湖北医药学院 抗肝癌药物亚硒酸酯化壳聚糖铜的一锅合成法及应用
CN110981940A (zh) * 2019-11-08 2020-04-10 复旦大学附属肿瘤医院 一种pd-l1结合剂、金属配合物及其使用方法和用途
US20220305146A1 (en) * 2021-03-26 2022-09-29 Vyripharm Enterprises, Inc. Radiopharmaceutical compositions and methods for infectious disease diagnosis and therapy
WO2023201377A2 (en) * 2022-04-15 2023-10-19 The General Hospital Corporation Scission-enhanced nuclear imaging and treatment

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE465907B (sv) * 1984-11-01 1991-11-18 Nyegaard & Co As Diagnosticeringsmedel innehaallande en paramagnetisk metall
US4861869A (en) 1986-05-29 1989-08-29 Mallinckrodt, Inc. Coupling agents for joining radionuclide metal ions with biologically useful proteins
US5707604A (en) * 1986-11-18 1998-01-13 Access Pharmaceuticals, Inc. Vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles
DK172391B1 (da) 1986-12-30 1998-05-18 Nihon Mediphysics Co Ltd Højmolekylær forbindelse til anvendelse som ikke-radioaktiv bærer, radioaktivt mærket højmolekylær forbindelse, fremgangsmåde til fremstilling deraf og fremgangsmåde til forbedret mærkning af en asialoglycoproteinacceptor-dirigerende forbindelse
US4965392A (en) 1987-03-26 1990-10-23 Neorx Corporation Chelating compounds for metal-radionuclide labeled proteins
US5364613A (en) * 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5116599A (en) 1989-07-31 1992-05-26 Johns Hopkins Univ. Perfluoro-t-butyl-containing compounds for use in fluorine-19 nmr and/or mri
DE69130182T2 (de) 1990-04-17 1999-01-28 Mallinckrodt Medical Inc Methode und reagentien um technetium-99m-komplexe herzustellen
DE59104905D1 (de) * 1990-06-01 1995-04-13 Diagnostikforschung Inst 99m-Tc-CYCLOPENTADIENYLCARBONYL -KOMPLEXE, VERFAHREN ZU IHRER HERSTELLUNG SOWIE IHRE VERWENDUNG IN DER DIAGNOSTIK.
CA2089519C (en) * 1990-08-17 2000-01-11 Kazuhiro Inoue N-acetylcarboxymethylchitosan derivatives and process for preparation thereof
JP2894879B2 (ja) * 1991-10-04 1999-05-24 日本メジフィジックス株式会社 診断用造影剤
EP0665729B1 (en) * 1992-09-04 2003-05-07 The General Hospital Corporation Biocompatible polymers containing diagnostic or therapeutic moieties
US5605672A (en) 1993-06-09 1997-02-25 The General Hospital Corporation Blood pool imaging composition and method of its use
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US5955053A (en) 1996-05-06 1999-09-21 Emory University Metal chelates as pharmaceutical imaging agents, processes of making such and uses thereof
US5986074A (en) 1996-05-06 1999-11-16 Emory University Metal chelates as pharmaceutical imaging agents, processes of making such and uses thereof
US5900228A (en) 1996-07-31 1999-05-04 California Institute Of Technology Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye
WO1999018938A1 (en) * 1997-10-09 1999-04-22 Perio Products Ltd. Delayed total release gastrointestinal drug delivery system
WO1999020316A1 (en) * 1997-10-20 1999-04-29 Board Of Regents, The University Of Texas System Single photon-emitting radiotraces and methods for their use
AU3870099A (en) * 1998-04-28 1999-11-16 Jagotec Ag Hyaluronan-based imaging agents
US6806260B1 (en) * 1998-11-10 2004-10-19 Netech, Inc. Functional chitosan derivative
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US6692724B1 (en) 1999-10-25 2004-02-17 Board Of Regents, The University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US6399951B1 (en) 2000-02-02 2002-06-04 Ut-Battelle, Llc Simultaneous CT and SPECT tomography using CZT detectors
AU2001254550A1 (en) 2000-04-20 2001-11-07 The University Of British Columbia Radiometal complexes of 2-pyrrolylthiones for imaging a therapy
EP1347784A2 (en) 2000-11-03 2003-10-01 Bristol-Myers Squibb Pharma Company Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation
US6623721B2 (en) 2000-12-18 2003-09-23 Draximage, Inc. Bifunctional chelating compounds containing hydroxamic acid residues
WO2002087498A2 (en) * 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Diagnostic imaging compositions, their methods of synthesis and use
GB0111204D0 (en) 2001-05-08 2001-06-27 Mertek Ltd High flux,high energy photon source
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
EP1478406B1 (en) 2002-02-27 2011-01-05 PharmaIN Corporation Compositions for delivery of therapeutics and other materials, and methods of making and using the same
AU2003230750A1 (en) 2002-03-29 2003-10-13 Threshold Pharmaceuticals, Inc. Compositions and methods for treating cancer
JP2005531647A (ja) * 2002-04-11 2005-10-20 カルボマー インク 新規なイメージングプローブ
US20040022729A1 (en) * 2002-07-31 2004-02-05 Uzgiris Egidijus E. Method for binding molecular agents to angiogencic blood vessels
US20040042959A1 (en) 2002-08-28 2004-03-04 Michael Montalto Imaging cell death in vivo using non-radionuclide contrast agents
US7303741B2 (en) 2002-09-23 2007-12-04 General Electric Company Systems and methods for high-resolution in vivo imaging of biochemical activity in a living organism
EP2316493A3 (en) 2002-11-07 2011-08-10 Board of Regents, The University of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US20050024380A1 (en) 2003-07-28 2005-02-03 Lin Lin Method for reducing random access memory of IC in display devices
US7790141B2 (en) * 2003-08-11 2010-09-07 Pathak Holdings, Llc Radio-opaque compounds, compositions containing same and methods of their synthesis and use
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
US20050265922A1 (en) * 2004-04-20 2005-12-01 Emory University Multimodality nanostructures, methods of fabrication thereof, and methods of use thereof

Also Published As

Publication number Publication date
AU2006204045B2 (en) 2010-10-14
WO2006074272A2 (en) 2006-07-13
AU2011200132B2 (en) 2012-10-11
WO2006074272A8 (en) 2006-12-28
JP2008531755A (ja) 2008-08-14
CN101137398B (zh) 2012-07-04
NO20074025L (no) 2007-09-27
IL184415A0 (en) 2008-12-29
US20120276005A1 (en) 2012-11-01
AU2006204045A1 (en) 2006-07-13
KR20070106711A (ko) 2007-11-05
US20060182687A1 (en) 2006-08-17
EP1846042A2 (en) 2007-10-24
CA2593256A1 (en) 2006-07-13
KR101313712B1 (ko) 2013-10-01
US8147805B2 (en) 2012-04-03
CN101137398A (zh) 2008-03-05
WO2006074272A3 (en) 2007-05-31
AU2011200132A1 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
BRPI0606395A2 (pt) conjugados para ambas imagem e radioquimioterapia: composição, fabricação e aplicações
AU2006226733A8 (en) Antibodies against CD38 for treatment of multiple myeloma
EP3466416A3 (en) A binding moiety-drug conjugate comprising a hsp90 binding moiety and a cytotoxic effector moiety
MX2010005022A (es) Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas.
MX355181B (es) Anticuerpos humanos contra el factor tisular.
BR112015021838A2 (pt) amatoxina, método de síntese, composição farmacêutica
WO2006119365A3 (en) Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
BRPI0512928A (pt) composições e métodos para liberação de agentes de antitumor
NO20073790L (no) Kjemiske forbindelser
NO20073788L (no) Kjemiske forbindelser
WO2008045604A3 (en) Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
BRPI0911383A2 (pt) miméticos de alfa hélice e métodos relacionados a eles
BR112021025720A2 (pt) Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados
WO2010046900A3 (en) Rgd-containing peptidomimetics and uses thereof
WO2015066053A3 (en) Targeted therapeutics
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
MX2021013251A (es) Tintes de cianina modificados y conjugados de los mismos.
BR112022005026A2 (pt) Conjugados terapêuticos
EA200800948A1 (ru) Биотиндиаминопроизводные и их конъюгаты с макроциклическими хелатирующими реагентами
WO2018236781A3 (en) Targeted therapeutics
IL185653A0 (en) Pharmaceutical compositions containing an antibody which binds the stalk region of kim-1
WO2008100848A3 (en) Novel agent for in vivo pet imaging of tumor proliferation
WO2008136850A3 (en) Cobalamin conjugates useful as imaging and therapeutic agents

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2287 DE 04/11/2014.